FIBROGEN WKN: A12EZ0 ISIN: US31572Q8087 Kürzel: 1FG Forum: Aktien Thema: Hauptdiskussion

FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results https://www.globenewswire.com/news-release/2023/02/27/2616460/33525/en/FibroGen-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results.html • Topline Data from Five Pivotal Phase 3 Trials in 2023 • Total Company Revenue $140.7 Million in 2022 • Continued Strong Roxadustat Volume Growth in China

William Blair Upgrades FibroGen to Outperform https://www.benzinga.com/news/23/01/30636166/william-blair-upgrades-fibrogen-to-outperform

FibroGen boosted to outperform at Raymond James on idiopathic pulmonary fibrosis candidate https://seekingalpha.com/news/3928500-fibrogen-boosted-to-outperform-at-raymond-james-on-idiopathic-pulmonary-fibrosis-candidate • Raymond James has upgraded FibroGen to outperform from market perform as it sees bullish prospects for phase 3 idiopathic pulmonary fibrosis (IPF) candidate pamrevlumab. • The firm has a $35 price target (69% upside based on Wednesday's close). ... • Analyst Danielle Brill is optimistic on phase 3 data for pamrevlumab given de-risking provided by phase 2 data. The mid-stage trial lasted for 48 weeks. • She added that given current treatments for IPF don't do much to halt disease progression and are marred by tolerability issues, pamrevlumab, which is given every three weeks via injection, will have a role based on discussions with key opinion leaders. • Brill noted that if the phase 3 trial is successful -- similar efficacy to standard of care but with a better safety profile -- the stock could break $50.

https://m.marketscreener.com/quote/stock/FIBROGEN-INC-18537026/news/Raymond-James-Upgrades-FibroGen-to-Outperform-From-Market-Perform-Price-Target-is-35-42820563/

https://www.marketbeat.com/instant-alerts/nasdaq-fgen-a-buy-or-sell-right-now-2023-01/

FibroGen GAAP EPS of -$0.98 misses by $0.16, revenue of $15.7M misses by $15.89M https://seekingalpha.com/news/3903012-fibrogen-gaap-eps-of-0_98-misses-0_16-revenue-of-15_7m-misses-15_89m • FibroGen press release (NASDAQ:FGEN): Q3 GAAP EPS of -$0.98 misses by $0.16. • Revenue of $15.7M (-89.9% Y/Y) misses by $15.89M. • At September 30, 2022, FibroGen had $441.6 million in cash - defined as cash, cash equivalents, investments, and accounts receivable.

FibroGen Reports Third Quarter 2022 Financial Results https://www.globenewswire.com/news-release/2022/11/07/2550183/33525/en/FibroGen-Reports-Third-Quarter-2022-Financial-Results.html • Continued advancement of pamrevlumab clinical trials – topline data from five pivotal Phase 3 trials beginning in 1H 2023 through mid-2024 • Completed enrollment of MATTERHORN Phase 3 study of roxadustat in patients with anemia of myelodysplastic syndromes with topline data expected 1H 2023 • Strong roxadustat volume growth in China of over 80% vs 3Q 2021

FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management https://www.globenewswire.com/news-release/2022/11/07/2550172/33525/en/FibroGen-Announces-50-Million-Royalty-Monetization-Financing-with-NovaQuest-Capital-Management.html • Strengthens balance sheet with strategic non-dilutive capital to support strategic priorities • Supported by global launches of EVRENZO™ in the territories partnered with Astellas Pharma Inc. • FibroGen will receive $50 million in total cash upfront

FibroGen GAAP EPS of -$0.78 beats by $0.19, revenue of $29.81M misses by $6.34M https://seekingalpha.com/news/3869168-fibrogen-gaap-eps-of-0_78-beats-0_19-revenue-of-29_81m-misses-6_34m • FibroGen press release (NASDAQ:FGEN): Q2 GAAP EPS of -$0.78 beats by $0.19. • Revenue of $29.81M (+22.4% Y/Y) misses by $6.34M.

FibroGen Reports Second Quarter 2022 Financial Results https://www.globenewswire.com/news-release/2022/08/08/2494238/33525/en/FibroGen-Reports-Second-Quarter-2022-Financial-Results.html • Completed enrollment of LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with Duchenne muscular dystrophy • 2Q 2022 revenue of $29.8 million, growth of 22% vs. 2Q 2021 • Continued significant roxadustat volume growth in China ...

https://www.globenewswire.com/news-release/2022/06/08/2458555/33525/en/FibroGen-Announces-Completion-of-Patient-Enrollment-in-LELANTOS-2-a-Phase-3-Clinical-Study-of-Pamrevlumab-in-Duchenne-Muscular-Dystrophy.html FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy

📌📌📌

FibroGen GAAP EPS of -$0.68 beats by $0.24, revenue of $60.8M beats by $32.04M https://seekingalpha.com/news/3835294-fibrogen-gaap-eps-of-0_68-beats-0_24-revenue-of-60_8m-beats-32_04m • FibroGen press release (NASDAQ:FGEN): Q1 GAAP EPS of -$0.68 beats by $0.24. • Revenue of $60.8M (+58.2% Y/Y) beats by $32.04M. • Based on our latest forecast, we estimate a 2022 ending cash balance of $310-340 million.

FibroGen Reports First Quarter 2022 Financial Results https://www.globenewswire.com/news-release/2022/05/09/2439011/33525/en/FibroGen-Reports-First-Quarter-2022-Financial-Results.html • Completed enrollment in ZEPHYRUS-1 Phase 3 study of pamrevlumab in idiopathic pulmonary fibrosis • 1Q 2022 revenue of $60.8M, growth of 58% vs. 1Q 2021 • Significant roxadustat volume growth in China in first quarter 2022 offsetting NRDL price reduction

FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results https://www.globenewswire.com/news-release/2022/02/28/2393644/33525/en/FibroGen-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results.html • Completed enrollment in LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer • Completed enrollment in LELANTOS-1 Phase 3 study of pamrevlumab in Duchenne muscular dystrophy • Total company revenue increased from $176.3 million in 2020 to $235.3 million in 2021

https://www.globenewswire.com/news-release/2021/12/20/2355186/33525/en/FibroGen-Exercises-Exclusive-License-Option-for-HiFiBiO-s-CCR8-Program.html